APO Research
Talk to an analyst

APO RESEARCH · REPORT

Classical Swine Fever Vaccines

It is a type of vaccine for classical swine fever. Classical swine fever (CSF), also known as hog cholera, is a contagious viral disease of pigs, including wild boar. The causative virus is a member of the genus Pestivirus of the family Flaviviridae, and is closely related to the viruses of bovine viral diarrhoea and border disease. There is only one serotype of CSF virus (CSFV).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

It is a type of vaccine for classical swine fever. Classical swine fever (CSF), also known as hog cholera, is a contagious viral disease of pigs, including wild boar. The causative virus is a member of the genus Pestivirus of the family Flaviviridae, and is closely related to the viruses of bovine viral diarrhoea and border disease. There is only one serotype of CSF virus (CSFV).

Selected research

Market Structure

Global Classical Swine Fever Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchClassical Swine Fever Vaccines Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Classical Swine Fever Vaccines Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Classical Swine Fever Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Classical Swine Fever Vaccines Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Classical Swine Fever Vaccines Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

It is a type of vaccine for classical swine fever. Classical swine fever (CSF), also known as hog cholera, is a contagious viral disease of pigs, including wild boar. The causative virus is a member of the genus Pestivirus of the family Flaviviridae, and is closely related to the viruses of bovine viral diarrhoea and border disease. There is only one serotype of CSF virus (CSFV).

The global classical swine fever vaccine market is dominated by Winsun, Merial and CAHIC, with the top three manufacturers accounting for about 60% of the market share. Asia Pacific is the largest market for classical swine fever vaccines, with a market share of about 50%, followed by Europe with a market share of about 25%. Tissue Culture Origin is the main type, with a share about 60%. Market Sales is the main application, which holds a share about 95%.

This report provides an overview of the global Classical Swine Fever Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Classical Swine Fever Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Classical Swine Fever Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Classical Swine Fever Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Classical Swine Fever Vaccines Segment by Company

WINSUN

Merial

CAHIC

Chopper Biology

MSD Animal Health (Merck)

ChengDu Tecbond

Ceva

Harbin Veterinary Research Institute

Qilu Animal Health Products Factory

Ringpu Biology

DHN

CAVAC

Komipharm

Agrovet

Bioveta

Jinyu Bio-Technology

Institutul Pasteur

MVP

Tecon

Classical Swine Fever Vaccines Segment by Source

Tissue Culture Origin

Cell Line Origin

Classical Swine Fever Vaccines Segment by Sales Channel

Government Tender

Market Sales

Classical Swine Fever Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Classical Swine Fever Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Classical Swine Fever Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Classical Swine Fever Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Classical Swine Fever Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Classical Swine Fever Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Classical Swine Fever Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Classical Swine Fever Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Classical Swine Fever Vaccines Industry Trends Table 2. Classical Swine Fever Vaccines Industry Drivers Table 3. Classical Swine Fever Vaccines Industry Opportunities and Challenges Table 4. Classical Swine Fever Vaccines Industry Restraints Table 5. Global Classical Swine Fever Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Classical Swine Fever Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Classical Swine Fever Vaccines Sales by Manufacturers (M Doses) & (2021-2026) Table 8. Global Classical Swine Fever Vaccines Sales Market Share by Manufacturers Table 9. Global Classical Swine Fever Vaccines Average Sales Price (US$/K Doses) of Manufacturers (2021-2026) Table 10. Global Classical Swine Fever Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Classical Swine Fever Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Classical Swine Fever Vaccines Manufacturers, Product Type & Application Table 13. Global Classical Swine Fever Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Classical Swine Fever Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tissue Culture Origin Table 17. Major Manufacturers of Cell Line Origin Table 18. Global Classical Swine Fever Vaccines Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 19. Global Classical Swine Fever Vaccines Sales by Type (2021-2026) & (M Doses) Table 20. Global Classical Swine Fever Vaccines Sales by Type (2027-2032) & (M Doses) Table 21. Global Classical Swine Fever Vaccines Sales Market Share by Type (2021-2026) Table 22. Global Classical Swine Fever Vaccines Sales Market Share by Type (2027-2032) Table 23. Global Classical Swine Fever Vaccines Revenue by Type 2021 VS 2025 VS 2032 (M Doses) Table 24. Global Classical Swine Fever Vaccines Revenue by Type (2021-2026) & (M Doses) Table 25. Global Classical Swine Fever Vaccines Revenue by Type (2027-2032) & (M Doses) Table 26. Global Classical Swine Fever Vaccines Revenue Market Share by Type (2021-2026) Table 27. Global Classical Swine Fever Vaccines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Government Tender Table 29. Major Manufacturers of Market Sales Table 30. Global Classical Swine Fever Vaccines Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 31. Global Classical Swine Fever Vaccines Sales by Application (2021-2026) & (M Doses) Table 32. Global Classical Swine Fever Vaccines Sales by Application (2027-2032) & (M Doses) Table 33. Global Classical Swine Fever Vaccines Sales Market Share by Application (2021-2026) Table 34. Global Classical Swine Fever Vaccines Sales Market Share by Application (2027-2032) Table 35. Global Classical Swine Fever Vaccines Revenue by Application 2021 VS 2025 VS 2032 (M Doses) Table 36. Global Classical Swine Fever Vaccines Revenue by Application (2021-2026) & (M Doses) Table 37. Global Classical Swine Fever Vaccines Revenue by Application (2027-2032) & (M Doses) Table 38. Global Classical Swine Fever Vaccines Revenue Market Share by Application (2021-2026) Table 39. Global Classical Swine Fever Vaccines Revenue Market Share by Application (2027-2032) Table 40. Global Classical Swine Fever Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 41. Global Classical Swine Fever Vaccines Sales by Region (2021-2026) & (M Doses) Table 42. Global Classical Swine Fever Vaccines Sales Market Share by Region (2021-2026) Table 43. Global Classical Swine Fever Vaccines Sales Forecasted by Region (2027-2032) & (M Doses) Table 44. Global Classical Swine Fever Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 46. North America Classical Swine Fever Vaccines Sales by Country (2021-2026) & (M Doses) Table 47. North America Classical Swine Fever Vaccines Sales by Country (2027-2032) & (M Doses) Table 48. Europe Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 49. Europe Classical Swine Fever Vaccines Sales by Country (2021-2026) & (M Doses) Table 50. Europe Classical Swine Fever Vaccines Sales by Country (2027-2032) & (M Doses) Table 51. Asia Pacific Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 52. Asia Pacific Classical Swine Fever Vaccines Sales by Country (2021-2026) & (M Doses) Table 53. Asia Pacific Classical Swine Fever Vaccines Sales by Country (2027-2032) & (M Doses) Table 54. South America, Middle East and Africa Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 55. South America, Middle East and Africa Classical Swine Fever Vaccines Sales by Country (2021-2026) & (M Doses) Table 56. South America, Middle East and Africa Classical Swine Fever Vaccines Sales by Country (2027-2032) & (M Doses) Table 57. Global Classical Swine Fever Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Classical Swine Fever Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Classical Swine Fever Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Classical Swine Fever Vaccines Revenue Market Share by Region (2021-2026) Table 61. Global Classical Swine Fever Vaccines Revenue Market Share by Region (2027-2032) Table 62. WINSUN Company Information Table 63. WINSUN Business Overview Table 64. WINSUN Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. WINSUN Classical Swine Fever Vaccines Product Portfolio Table 66. WINSUN Recent Development Table 67. Merial Company Information Table 68. Merial Business Overview Table 69. Merial Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Merial Classical Swine Fever Vaccines Product Portfolio Table 71. Merial Recent Development Table 72. CAHIC Company Information Table 73. CAHIC Business Overview Table 74. CAHIC Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. CAHIC Classical Swine Fever Vaccines Product Portfolio Table 76. CAHIC Recent Development Table 77. Chopper Biology Company Information Table 78. Chopper Biology Business Overview Table 79. Chopper Biology Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Chopper Biology Classical Swine Fever Vaccines Product Portfolio Table 81. Chopper Biology Recent Development Table 82. MSD Animal Health (Merck) Company Information Table 83. MSD Animal Health (Merck) Business Overview Table 84. MSD Animal Health (Merck) Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. MSD Animal Health (Merck) Classical Swine Fever Vaccines Product Portfolio Table 86. MSD Animal Health (Merck) Recent Development Table 87. ChengDu Tecbond Company Information Table 88. ChengDu Tecbond Business Overview Table 89. ChengDu Tecbond Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. ChengDu Tecbond Classical Swine Fever Vaccines Product Portfolio Table 91. ChengDu Tecbond Recent Development Table 92. Ceva Company Information Table 93. Ceva Business Overview Table 94. Ceva Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Ceva Classical Swine Fever Vaccines Product Portfolio Table 96. Ceva Recent Development Table 97. Harbin Veterinary Research Institute Company Information Table 98. Harbin Veterinary Research Institute Business Overview Table 99. Harbin Veterinary Research Institute Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Harbin Veterinary Research Institute Classical Swine Fever Vaccines Product Portfolio Table 101. Harbin Veterinary Research Institute Recent Development Table 102. Qilu Animal Health Products Factory Company Information Table 103. Qilu Animal Health Products Factory Business Overview Table 104. Qilu Animal Health Products Factory Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Qilu Animal Health Products Factory Classical Swine Fever Vaccines Product Portfolio Table 106. Qilu Animal Health Products Factory Recent Development Table 107. Ringpu Biology Company Information Table 108. Ringpu Biology Business Overview Table 109. Ringpu Biology Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Ringpu Biology Classical Swine Fever Vaccines Product Portfolio Table 111. Ringpu Biology Recent Development Table 112. DHN Company Information Table 113. DHN Business Overview Table 114. DHN Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. DHN Classical Swine Fever Vaccines Product Portfolio Table 116. DHN Recent Development Table 117. CAVAC Company Information Table 118. CAVAC Business Overview Table 119. CAVAC Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. CAVAC Classical Swine Fever Vaccines Product Portfolio Table 121. CAVAC Recent Development Table 122. Komipharm Company Information Table 123. Komipharm Business Overview Table 124. Komipharm Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Komipharm Classical Swine Fever Vaccines Product Portfolio Table 126. Komipharm Recent Development Table 127. Agrovet Company Information Table 128. Agrovet Business Overview Table 129. Agrovet Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Agrovet Classical Swine Fever Vaccines Product Portfolio Table 131. Agrovet Recent Development Table 132. Bioveta Company Information Table 133. Bioveta Business Overview Table 134. Bioveta Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Bioveta Classical Swine Fever Vaccines Product Portfolio Table 136. Bioveta Recent Development Table 137. Jinyu Bio-Technology Company Information Table 138. Jinyu Bio-Technology Business Overview Table 139. Jinyu Bio-Technology Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Jinyu Bio-Technology Classical Swine Fever Vaccines Product Portfolio Table 141. Jinyu Bio-Technology Recent Development Table 142. Institutul Pasteur Company Information Table 143. Institutul Pasteur Business Overview Table 144. Institutul Pasteur Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Institutul Pasteur Classical Swine Fever Vaccines Product Portfolio Table 146. Institutul Pasteur Recent Development Table 147. MVP Company Information Table 148. MVP Business Overview Table 149. MVP Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. MVP Classical Swine Fever Vaccines Product Portfolio Table 151. MVP Recent Development Table 152. Tecon Company Information Table 153. Tecon Business Overview Table 154. Tecon Classical Swine Fever Vaccines Sales (M Doses), Price (US$/K Doses), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Tecon Classical Swine Fever Vaccines Product Portfolio Table 156. Tecon Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Classical Swine Fever Vaccines Distributors List Table 160. Classical Swine Fever Vaccines Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Classical Swine Fever Vaccines Product Image Figure 2. Global Classical Swine Fever Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Classical Swine Fever Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Classical Swine Fever Vaccines Sales (2021-2032) & (M Doses) Figure 5. Global Classical Swine Fever Vaccines Average Price (US$/K Doses) & (2021-2032) Figure 6. Global Top 5 and 10 Classical Swine Fever Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tissue Culture Origin Image Figure 9. Cell Line Origin Image Figure 10. Global Classical Swine Fever Vaccines Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 11. Global Classical Swine Fever Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Classical Swine Fever Vaccines Sales Market Share by Type (2021-2032) Figure 13. Global Classical Swine Fever Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 14. Global Classical Swine Fever Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Classical Swine Fever Vaccines Revenue Market Share by Type (2021-2032) Figure 16. Government Tender Image Figure 17. Market Sales Image Figure 18. Global Classical Swine Fever Vaccines Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 19. Global Classical Swine Fever Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Classical Swine Fever Vaccines Sales Market Share by Application (2021-2032) Figure 21. Global Classical Swine Fever Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 22. Global Classical Swine Fever Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Classical Swine Fever Vaccines Revenue Market Share by Application (2021-2032) Figure 24. North America Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 25. North America Classical Swine Fever Vaccines Sales Market Share by Country (2021-2032) Figure 26. U.S. Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 27. Canada Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 28. Mexico Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 29. Europe Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 30. Europe Classical Swine Fever Vaccines Sales Market Share by Country (2021-2032) Figure 31. Germany Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 32. France Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 33. U.K. Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 34. Italy Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 35. Netherlands Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 36. Asia Pacific Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 37. Asia Pacific Classical Swine Fever Vaccines Sales Market Share by Country (2021-2032) Figure 38. China Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 39. Japan Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 40. South Korea Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 41. Southeast Asia Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 42. India Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 43. Australia Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 44. South America, Middle East and Africa Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 45. South America, Middle East and Africa Classical Swine Fever Vaccines Sales Market Share by Country (2021-2032) Figure 46. Brazil Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 47. South Africa Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 48. Saudi Arabia Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 49. Turkey Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 50. Argentina Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 51. UAE Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 52. Egypt Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 53. Chile Classical Swine Fever Vaccines Sales and Growth Rate (2021-2032) & (M Doses) Figure 54. Global Classical Swine Fever Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Classical Swine Fever Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Classical Swine Fever Vaccines Revenue (2021-2032) & (US$ Million) Figure 57. North America Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Classical Swine Fever Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. Europe Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Classical Swine Fever Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Classical Swine Fever Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Classical Swine Fever Vaccines Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Classical Swine Fever Vaccines Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Tissue Culture Origin
  • Cell Line Origin
Applications
  • Government Tender
  • Market Sales
Companies covered
  • WINSUN
  • Merial
  • CAHIC
  • Chopper Biology
  • MSD Animal Health (Merck)
  • ChengDu Tecbond
  • Ceva
  • Harbin Veterinary Research Institute
  • Qilu Animal Health Products Factory
  • Ringpu Biology
  • DHN
  • CAVAC
  • Komipharm
  • Agrovet
  • Bioveta
  • Jinyu Bio-Technology
  • Institutul Pasteur
  • MVP
  • Tecon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Classical Swine Fever Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Classical Swine Fever Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Classical Swine Fever Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Classical Swine Fever Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Classical Swine Fever Vaccines Market Dynamics
  1. 2.1 Classical Swine Fever Vaccines Industry Trends
  2. 2.2 Classical Swine Fever Vaccines Industry Drivers
  3. 2.3 Classical Swine Fever Vaccines Industry Opportunities and Challenges
  4. 2.4 Classical Swine Fever Vaccines Industry Restraints
3 Classical Swine Fever Vaccines Market by Manufacturers
  1. 3.1 Global Classical Swine Fever Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Classical Swine Fever Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Classical Swine Fever Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Classical Swine Fever Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Classical Swine Fever Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Classical Swine Fever Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Classical Swine Fever Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Classical Swine Fever Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Classical Swine Fever Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Classical Swine Fever Vaccines Tier 1, Tier 2, and Tier 3
4 Classical Swine Fever Vaccines Market by Type
  1. 4.1 Classical Swine Fever Vaccines Type Introduction
  2. 4.1.1 Tissue Culture Origin
  3. 4.1.2 Cell Line Origin
  4. 4.2 Global Classical Swine Fever Vaccines Sales by Type
  5. 4.2.1 Global Classical Swine Fever Vaccines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Classical Swine Fever Vaccines Sales by Type (2021-2032)
  7. 4.2.3 Global Classical Swine Fever Vaccines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Classical Swine Fever Vaccines Revenue by Type
  9. 4.3.1 Global Classical Swine Fever Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Classical Swine Fever Vaccines Revenue by Type (2021-2032)
  11. 4.3.3 Global Classical Swine Fever Vaccines Revenue Market Share by Type (2021-2032)
5 Classical Swine Fever Vaccines Market by Application
  1. 5.1 Classical Swine Fever Vaccines Application Introduction
  2. 5.1.1 Government Tender
  3. 5.1.2 Market Sales
  4. 5.2 Global Classical Swine Fever Vaccines Sales by Application
  5. 5.2.1 Global Classical Swine Fever Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Classical Swine Fever Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global Classical Swine Fever Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Classical Swine Fever Vaccines Revenue by Application
  9. 5.3.1 Global Classical Swine Fever Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Classical Swine Fever Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global Classical Swine Fever Vaccines Revenue Market Share by Application (2021-2032)
6 Global Classical Swine Fever Vaccines Sales by Region
  1. 6.1 Global Classical Swine Fever Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Classical Swine Fever Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Classical Swine Fever Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Classical Swine Fever Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Classical Swine Fever Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Classical Swine Fever Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Classical Swine Fever Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Classical Swine Fever Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Classical Swine Fever Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Classical Swine Fever Vaccines Revenue by Region
  1. 7.1 Global Classical Swine Fever Vaccines Revenue by Region
  2. 7.1.1 Global Classical Swine Fever Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Classical Swine Fever Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Classical Swine Fever Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Classical Swine Fever Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Classical Swine Fever Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Classical Swine Fever Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Classical Swine Fever Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Classical Swine Fever Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Classical Swine Fever Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 WINSUN
  2. 8.1.1 WINSUN Company Information
  3. 8.1.2 WINSUN Business Overview
  4. 8.1.3 WINSUN Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 WINSUN Classical Swine Fever Vaccines Product Portfolio
  6. 8.1.5 WINSUN Recent Developments
  7. 8.2 Merial
  8. 8.2.1 Merial Company Information
  9. 8.2.2 Merial Business Overview
  10. 8.2.3 Merial Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merial Classical Swine Fever Vaccines Product Portfolio
  12. 8.2.5 Merial Recent Developments
  13. 8.3 CAHIC
  14. 8.3.1 CAHIC Company Information
  15. 8.3.2 CAHIC Business Overview
  16. 8.3.3 CAHIC Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CAHIC Classical Swine Fever Vaccines Product Portfolio
  18. 8.3.5 CAHIC Recent Developments
  19. 8.4 Chopper Biology
  20. 8.4.1 Chopper Biology Company Information
  21. 8.4.2 Chopper Biology Business Overview
  22. 8.4.3 Chopper Biology Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chopper Biology Classical Swine Fever Vaccines Product Portfolio
  24. 8.4.5 Chopper Biology Recent Developments
  25. 8.5 MSD Animal Health (Merck)
  26. 8.5.1 MSD Animal Health (Merck) Company Information
  27. 8.5.2 MSD Animal Health (Merck) Business Overview
  28. 8.5.3 MSD Animal Health (Merck) Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MSD Animal Health (Merck) Classical Swine Fever Vaccines Product Portfolio
  30. 8.5.5 MSD Animal Health (Merck) Recent Developments
  31. 8.6 ChengDu Tecbond
  32. 8.6.1 ChengDu Tecbond Company Information
  33. 8.6.2 ChengDu Tecbond Business Overview
  34. 8.6.3 ChengDu Tecbond Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ChengDu Tecbond Classical Swine Fever Vaccines Product Portfolio
  36. 8.6.5 ChengDu Tecbond Recent Developments
  37. 8.7 Ceva
  38. 8.7.1 Ceva Company Information
  39. 8.7.2 Ceva Business Overview
  40. 8.7.3 Ceva Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ceva Classical Swine Fever Vaccines Product Portfolio
  42. 8.7.5 Ceva Recent Developments
  43. 8.8 Harbin Veterinary Research Institute
  44. 8.8.1 Harbin Veterinary Research Institute Company Information
  45. 8.8.2 Harbin Veterinary Research Institute Business Overview
  46. 8.8.3 Harbin Veterinary Research Institute Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Harbin Veterinary Research Institute Classical Swine Fever Vaccines Product Portfolio
  48. 8.8.5 Harbin Veterinary Research Institute Recent Developments
  49. 8.9 Qilu Animal Health Products Factory
  50. 8.9.1 Qilu Animal Health Products Factory Company Information
  51. 8.9.2 Qilu Animal Health Products Factory Business Overview
  52. 8.9.3 Qilu Animal Health Products Factory Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Qilu Animal Health Products Factory Classical Swine Fever Vaccines Product Portfolio
  54. 8.9.5 Qilu Animal Health Products Factory Recent Developments
  55. 8.10 Ringpu Biology
  56. 8.10.1 Ringpu Biology Company Information
  57. 8.10.2 Ringpu Biology Business Overview
  58. 8.10.3 Ringpu Biology Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ringpu Biology Classical Swine Fever Vaccines Product Portfolio
  60. 8.10.5 Ringpu Biology Recent Developments
  61. 8.11 DHN
  62. 8.11.1 DHN Company Information
  63. 8.11.2 DHN Business Overview
  64. 8.11.3 DHN Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 DHN Classical Swine Fever Vaccines Product Portfolio
  66. 8.11.5 DHN Recent Developments
  67. 8.12 CAVAC
  68. 8.12.1 CAVAC Company Information
  69. 8.12.2 CAVAC Business Overview
  70. 8.12.3 CAVAC Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CAVAC Classical Swine Fever Vaccines Product Portfolio
  72. 8.12.5 CAVAC Recent Developments
  73. 8.13 Komipharm
  74. 8.13.1 Komipharm Company Information
  75. 8.13.2 Komipharm Business Overview
  76. 8.13.3 Komipharm Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Komipharm Classical Swine Fever Vaccines Product Portfolio
  78. 8.13.5 Komipharm Recent Developments
  79. 8.14 Agrovet
  80. 8.14.1 Agrovet Company Information
  81. 8.14.2 Agrovet Business Overview
  82. 8.14.3 Agrovet Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Agrovet Classical Swine Fever Vaccines Product Portfolio
  84. 8.14.5 Agrovet Recent Developments
  85. 8.15 Bioveta
  86. 8.15.1 Bioveta Company Information
  87. 8.15.2 Bioveta Business Overview
  88. 8.15.3 Bioveta Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bioveta Classical Swine Fever Vaccines Product Portfolio
  90. 8.15.5 Bioveta Recent Developments
  91. 8.16 Jinyu Bio-Technology
  92. 8.16.1 Jinyu Bio-Technology Company Information
  93. 8.16.2 Jinyu Bio-Technology Business Overview
  94. 8.16.3 Jinyu Bio-Technology Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Jinyu Bio-Technology Classical Swine Fever Vaccines Product Portfolio
  96. 8.16.5 Jinyu Bio-Technology Recent Developments
  97. 8.17 Institutul Pasteur
  98. 8.17.1 Institutul Pasteur Company Information
  99. 8.17.2 Institutul Pasteur Business Overview
  100. 8.17.3 Institutul Pasteur Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Institutul Pasteur Classical Swine Fever Vaccines Product Portfolio
  102. 8.17.5 Institutul Pasteur Recent Developments
  103. 8.18 MVP
  104. 8.18.1 MVP Company Information
  105. 8.18.2 MVP Business Overview
  106. 8.18.3 MVP Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 MVP Classical Swine Fever Vaccines Product Portfolio
  108. 8.18.5 MVP Recent Developments
  109. 8.19 Tecon
  110. 8.19.1 Tecon Company Information
  111. 8.19.2 Tecon Business Overview
  112. 8.19.3 Tecon Classical Swine Fever Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Tecon Classical Swine Fever Vaccines Product Portfolio
  114. 8.19.5 Tecon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Classical Swine Fever Vaccines Value Chain Analysis
  2. 9.1.1 Classical Swine Fever Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Classical Swine Fever Vaccines Production Mode & Process
  6. 9.2 Classical Swine Fever Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Classical Swine Fever Vaccines Distributors
  9. 9.2.3 Classical Swine Fever Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst